Tuesday, November 17, 2026
RSS


← All Stories

Pharmaceutical

Kymera Therapeutics Sets Up Year-End Catalyst With KT-621 Data on Deck

Kymera’s third-quarter update pairs positive KT-579 Phase 1 results with a year-end 2026 KT-621 Phase 2b readout.

Oct 29, 2026
Pharmaceutical

Iovance Stock Jumps as Lifileucel Combination Delivers 62.5% Response Rate

Iovance’s frontline melanoma data could broaden lifileucel’s opportunity, but the result is not yet a commercial or regulatory conclusion.

Oct 29, 2026
Pharmaceutical

Cullinan Therapeutics’ FDA IND Clearance Moves Velinotamig Toward Global Autoimmune Trials

Cullinan Therapeutics’ FDA IND clearance moves velinotamig into global clinical development for autoimmune cytopenias, a key pipeline transi…

Oct 28, 2026
Pharmaceutical

Genmab ADR Surges 16.8% as Biotech Traders Revisit Catalyst and M&A Speculation

Genmab’s GMAB ADR surged 16.8% in morning trading, putting M&A speculation, catalysts and biotech peer sentiment back in focus.

Oct 28, 2026
Pharmaceutical

Eli Lilly’s Retatrutide Data Raises Stakes in the GLP-1 Drug Race

New retatrutide trial data may strengthen Eli Lilly’s position in the GLP-1 market, while raising expectations for its next-generation pipel…

Oct 28, 2026
Pharmaceutical

Moderna’s $181.36 Support Level Faces Test After Mixed Melanoma Data

Moderna is holding reported $181.36 support after mixed melanoma vaccine data narrowed the benefit seen in Phase 2b.

Oct 27, 2026
Pharmaceutical

Merck’s Phase III Oncology Results Put Its 2027 Pipeline Under the Microscope

Merck’s TroFuse-005 update puts its oncology pipeline at the center of the post-Keytruda growth debate heading into 2027.

Oct 27, 2026
Pharmaceutical

Incyte’s $152 Price Target Holds as H.C. Wainwright Reviews Cancer-Drug Data

H.C. Wainwright kept Incyte’s $152 price target after reviewing new cancer-drug data, signaling continued attention without a rating change.

Oct 27, 2026
Pharmaceutical

Summit Therapeutics’ $30 Target Holds as Ivonescimab Data Deliver Another Phase 3 Win

Back-to-back bullish analyst calls follow additional ivonescimab data, keeping Summit Therapeutics and its clinical catalyst profile in focu…

Oct 27, 2026
Pharmaceutical

Pfizer’s Talzenna-Xtandi Approval Expansion Adds New Oncology Catalyst for PFE

The FDA’s expanded approval of Pfizer’s Talzenna-Xtandi combination gives PFE a fresh regulatory catalyst in metastatic prostate cancer.

Oct 27, 2026
Pharmaceutical

SciSparc Stock Jumps 38.56% as Traders Track SCI-110 and AI Pivot

SciSparc shares rose 38.56% as traders focused on the SCI-110 trial and an AI pivot, though confirmed clinical and commercial details remain…

Oct 26, 2026
Pharmaceutical

Aurora Cannabis Investors Weigh Alberta Securities Commission Decision

The Alberta Securities Commission dismissed a Curaleaf application, giving Aurora investors a regulatory signal—but no reported earnings or …

Oct 26, 2026